Chertov et al., "A protease-resistant immunotoxin
against CD22 with greatly increased activity against CLL and diminished animal toxicity," Blood, vol.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin
and immune suppression.
and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors," Proceedings of the National Acadamy of Sciences of the United States of America, vol.
In the present study, we reported the novel immunotoxin
PT by fusing the scFv of Pan to 38 kDa truncated fragment of PE and investigated its potent antitumor potency against esophageal cancer cells in vitro and in vivo.
[sup] first reported a novel immunotoxin
that could kill cancer cells.
In order to determine whether all damages to ipRGCs were caused by the injection of immunotoxin
, or whether theses damages were also potentially related with age, we immunohistochemically labeled ipRGCs using antibodies against melanopsin and compared the number of ipRGCs on flat-mounted retina among 1-, 3-, and 6-month-old rd mice (n = 6 in each age group) (the detailed methodology is described below).
A multicenter, randomized, open-label Phase II study is currently ongoing in patients with recurrent GBM to evaluate efficacy of intratumoral administration of cpIL-4PE after surgical resection, with a secondary objective to evaluate safety and tolerability of this immunotoxin
(2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin
anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
Stirpe, "T lymphocyte killing by a xanthine-oxidase-containing immunotoxin
," Cancer Immunology, Immunotherapy, vol.
Cytotoxic activity of the recombinant anti-mesothelin immunotoxin
, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Half of the animals subsequently received a two-week dose of a genetically designed, HIV-specific poison, or immunotoxin
, to complement the antiretrovirals, while the other half continued receiving antiretrovirals alone.